Amylase/Papain: A Provider Briefing on Availability in 2026

If your patients have been reporting difficulty finding Amylase/Papain digestive enzyme supplements, they're reflecting a real trend. While this over-the-counter combination product is not subject to a formal FDA shortage listing, availability has been inconsistent across retail channels throughout 2025 and into 2026.

This briefing covers the factors driving availability challenges, prescribing implications, cost and access considerations, and tools you can use to help your patients navigate the current landscape.

Background: What Is Amylase/Papain?

Amylase/Papain is an OTC digestive enzyme supplement combining Alpha Amylase (a carbohydrate-digesting enzyme) and Papain (a proteolytic enzyme derived from Carica papaya). Patients use it primarily for symptomatic relief of:

• Dyspepsia (functional indigestion)
• Post-prandial bloating and abdominal distension
• Flatulence
• General digestive discomfort

The product is classified as a dietary supplement, not an FDA-approved drug, which means it does not undergo the same regulatory approval, manufacturing oversight, or shortage tracking as prescription medications.

Timeline of Availability Issues

Key developments affecting Amylase/Papain supply:

• 2008 — FDA issued enforcement action against unapproved topical drug products containing Papain, citing serious allergic reactions including anaphylaxis. This affected wound-care products (e.g., Accuzyme), not oral supplements, but created market confusion.
• 2023-2024 — Rising global demand for digestive enzyme supplements (market valued at $850+ million in 2024) began putting pressure on raw material supply chains.
• 2025 — Intermittent retail stockouts reported for several leading brands of Amylase/Papain combination supplements, particularly at chain pharmacies.
• 2026 — Availability remains inconsistent. Products are generally obtainable through online retailers and specialty stores, but local pharmacy availability varies significantly by region.

Prescribing Implications

As a provider, there are several clinical considerations to keep in mind regarding Amylase/Papain:

OTC vs. Prescription Status

Amylase/Papain is available without a prescription. If patients report difficulty finding it, you don't need to write a prescription — but you can help by recommending specific brands, directing them to reliable retail channels, or recommending alternative enzyme products.

Drug Interactions

Papain has a documented moderate interaction with Warfarin and other anticoagulants. It may enhance the blood-thinning effect, increasing the risk of bruising and bleeding. If your patients are on anticoagulant therapy, monitor INR values if they begin or discontinue Papain-containing supplements. Bromelain, a common alternative, carries similar interaction potential.

Patients on antiplatelet agents (Aspirin, Clopidogrel) should also be counseled about potential additive effects.

Allergy Cross-Reactivity

Patients with known allergy to latex, fig, or kiwi may be at increased risk of allergic reaction to Papain due to cross-reactivity. The FDA's 2008 enforcement action on topical Papain products was partly driven by reports of anaphylaxis in sensitized patients. While the oral route carries lower risk, it is not zero — counsel accordingly.

Pregnancy Considerations

Papain is classified as possibly unsafe during pregnancy, with concerns about potential embryotoxic or teratogenic effects documented in animal studies. Advise pregnant patients or those planning pregnancy to avoid Papain-containing supplements.

Current Availability Picture

The supply situation varies by channel:

• Chain pharmacies (CVS, Walgreens, Rite Aid) — Inconsistent. Many locations carry generic digestive enzyme blends but may not stock specific Amylase/Papain combination products.
• Independent pharmacies — More likely to carry specialty supplement brands. Can also special-order products.
• Health food stores (Whole Foods, Sprouts, co-ops) — Generally good availability of plant-based enzyme products containing Papain.
• Online retailers (Amazon, iHerb, Vitacost) — Broadest selection and most consistent availability. Products range from $8 to $30 per bottle.

Cost and Access Considerations

Key cost factors to communicate to patients:

• OTC pricing: $8 to $30 per bottle (30-180 count), depending on brand and formulation
• Insurance: OTC digestive enzyme supplements are generally not covered by health insurance plans
• FSA/HSA eligibility: May be eligible with a Letter of Medical Necessity
• Prescription alternatives: If clinical indication warrants, Pancrelipase (Creon, Zenpep) is covered by most insurance plans for diagnosed exocrine pancreatic insufficiency. Cash price for Creon ranges from $800 to $1,500/month; AbbVie's Creon Cares program offers significant savings.

For patients facing cost barriers, direct them to our guide on saving money on Amylase/Papain.

Tools and Resources for Providers

The following tools can help you support patients who are having trouble finding Amylase/Papain:

• Medfinder for Providers — Search for supplement and medication availability at pharmacies near your practice or your patient's location. Share availability results directly with patients.
• NeedyMeds (needymeds.org) — Database of patient assistance programs, though primarily for prescription medications
• ConsumerLab (consumerlab.com) — Independent testing and reviews of digestive enzyme supplement quality and potency

Alternative Enzyme Products

When Amylase/Papain is unavailable, consider recommending:

• Bromelain — Plant-based proteolytic enzyme from pineapple; similar mechanism to Papain. OTC, $8-$20/bottle. Note: same Warfarin interaction potential.
• Multi-enzyme complexes — Products containing Amylase, Protease, Lipase, and Cellulase provide broader digestive support.
• Pancrelipase (Creon, Zenpep) — Prescription-strength option for patients with documented exocrine pancreatic insufficiency.
• Betaine HCl with Pepsin — For patients with suspected hypochlorhydria. Contraindicated in peptic ulcer disease and with concurrent NSAID use.

For a patient-friendly guide to alternatives, share our article on alternatives to Amylase/Papain.

Looking Ahead

The digestive enzyme supplement market is projected to grow at a CAGR of 6-8% through 2031, driven by increasing consumer awareness of gut health and rising incidence of digestive disorders. This growth trajectory suggests that supply pressures on products like Amylase/Papain may persist in the near term, though expanded manufacturing capacity should ease availability over time.

Key trends to watch:

• Expansion of plant-based and vegan enzyme formulations
• Development of delayed-release delivery systems for improved enzyme bioavailability
• Potential for FDA regulatory clarification regarding enzyme supplement quality standards

Final Thoughts

Amylase/Papain availability challenges in 2026 are driven by a combination of supply chain factors, growing demand, and retail distribution shifts — not by a traditional drug shortage. As a provider, you can help patients by directing them to reliable supply channels, monitoring for drug interactions (especially with anticoagulants), counseling on appropriate alternatives, and using tools like Medfinder for Providers to support medication access.

For a complementary guide on helping patients find this product, see our article on how to help your patients find Amylase/Papain in stock.